Fernando Pérez-Calvo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fernando Pérez-Calvo has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Elisabet Delgado-Sánchez
Infectious Diseases Unit, Sant Joan D’Alacant University Hospital, 03550 Sant Joan D’Alacant, Spain
1 shared publication - Francisco Jover
Miguel Hernández University, Infectious Diseases Unit, Spain; San Juan University Clinical Hospital, Alicante, Spain
1 shared publication - Jorge Peris-García
Universidad Miguel Hernández, Elche, Spain
1 shared publication - Mari Ángeles Bernabeu Martinez
Pharmacy Department, San Juan de Alicante University Hospital, 03550 San Juan de Alicante, Alicante, Spain
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in AIDS Research and Treatment
- Vol. 2025 (1) , 8818830
BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV‐Infected Patients
Objectives: Beyond initial antiretroviral therapy (ART), bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg (B/F/TAF) has been evaluated as an option for the continuation of treatment for virologically suppressed individuals who switch from other regimens. While treatment‐emergent resistance to bictegravir has not been observed in clinical trials, rare case reports have described resistance development during B/F/TAF therapy, typically in the context of suboptimal adherence. Its favourable safety profile, minimal drug–drug interactions and proven virological efficacy suggest that virologically suppressed individuals may benefit from switching to B/F/TAF. Methods: Descriptive, retrospective, observational study of adults with HIV infection receiving effective non‐INSTI (integrase strand transfer inhibitors)‐based ART who switched to a B/F/TAF, but not all were suppressed. We compared individuals’ viral loads, CD4+ lymphocyte counts, glomerular filtration rates, and lipid profiles before the switch and after 24 weeks of B/F/TAF. Safety was also assessed. Results: Seventy‐nine individuals switched from non‐INSTI‐based therapies to B/F/TAF. At 24 weeks after the switch, HIV‐1 RNA < 50 copies/mL was reported in 96.1% and 92.4% of participants per protocol and intention‐to‐treat analysis, respectively, compared to 81.0% at baseline. This represents a 15.1% increase in virologic suppression (viral load < 50 copies/mL) compared to baseline. No significant changes were detected in the CD4+ lymphocyte count, glomerular filtration rate, or lipid profile. Adverse events (AEs) were reported in 5.1% of patients. Three patients discontinued treatment due to AEs. Conclusions: The results of this study suggest that patients can switch to B/F/TAF from non‐INSTI‐based therapies without compromising the effectiveness or safety of ART.
- 1 January 2025
- Published by Wiley in AIDS Research and Treatment
- Vol. 2025 (1) , 8818830
Open AccessBIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV‐Infected Patients
Objectives: Beyond initial antiretroviral therapy (ART), bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg (B/F/TAF) has been evaluated as an option for the continuation of treatment for virologically suppressed individuals who switch from other regimens. While treatment‐emergent resistance to bictegravir has not been observed in clinical trials, rare case reports have described resistance development during B/F/TAF therapy, typically in the context of suboptimal adherence. Its favourable safety profile, minimal drug–drug interactions and proven virological efficacy suggest that virologically suppressed individuals may benefit from switching to B/F/TAF. Methods: Descriptive, retrospective, observational study of adults with HIV infection receiving effective non‐INSTI (integrase strand transfer inhibitors)‐based ART who switched to a B/F/TAF, but not all were suppressed. We compared individuals’ viral loads, CD4+ lymphocyte counts, glomerular filtration rates, and lipid profiles before the switch and after 24 weeks of B/F/TAF. Safety was also assessed. Results: Seventy‐nine individuals switched from non‐INSTI‐based therapies to B/F/TAF. At 24 weeks after the switch, HIV‐1 RNA < 50 copies/mL was reported in 96.1% and 92.4% of participants per protocol and intention‐to‐treat analysis, respectively, compared to 81.0% at baseline. This represents a 15.1% increase in virologic suppression (viral load < 50 copies/mL) compared to baseline. No significant changes were detected in the CD4+ lymphocyte count, glomerular filtration rate, or lipid profile. Adverse events (AEs) were reported in 5.1% of patients. Three patients discontinued treatment due to AEs. Conclusions: The results of this study suggest that patients can switch to B/F/TAF from non‐INSTI‐based therapies without compromising the effectiveness or safety of ART.